redhill biopharma's opaganib demonstrates complete inhibition of ads-cov-2
redhill biopharma's opaganib demonstrates complete inhibition of ads-cov-2
in addition to opaganib, redhills in-vitro study evaluated the antiviral activity of its phase-2 stage investigational drug, rhb-107 (upamostat), a serine protease inhibitor active against a number of human serine proteases, with results demonstrating potent inhibition of sars-cov-2 viral replication.